Navigation Links
Molecular fingerprint of breast-cancer drug resistance can predict response to treatment
Date:9/24/2007

Barcelona, Spain: A way of predicting which patients will respond well to treatment with a common chemotherapy drug used in breast cancer was unveiled at the European Cancer Conference (ECCO 14) today (Monday 24 September). Dr Iain Brown, from the University of Aberdeen, Aberdeen, Scotland, told the conference that he and his colleague, Dr Andrew Schofield, had identified two genes that could identify which cells would be resistant and which would respond to docetaxel.

Docetaxel is one of the most effective chemotherapy treatments in advanced breast cancer. It works by binding to cell components called microtubules, and stabilising them so that they do not disassemble. They then accumulate within the cell and bring about apoptosis, or cell death. However, up to half of all patients treated with this drug will develop resistance, and hence the treatment will fail, said Dr Brown.

The scientists decided to look for a specific genetic make-up in patients where docetaxel treatment had failed, in the hope that this might explain why they became resistant to the drug. They used micro-array analysis, a technique that allowed them to look at every known gene in our cells at once, to identify genes that were significantly associated with such resistance.

By going back to the laboratory, using breast cancer cell lines, we can eliminate much of the variation in gene expression found in different patients, and thus remove a lot of background noise, said Dr Brown. We developed a unique model of docetaxel resistance in breast cancer from two different cell lines made resistant to the drug by exposing them to increasing concentrations of the drug. This model has also allowed us to test cells which are resistant to low levels of the drug and cells which are resistant to high levels.

Drs Brown and Schofield now intend to carry the research further, by applying their findings to patient samples to see whether the gene set they have discovered has the ability to predict response to docetaxel in a patient who has undergone treatment with the drug. At the moment we have only tested this in cell lines, said Dr Brown, but we do believe these results may be translated into the clinical setting and benefit the patient. In essence, we have taken a clinical problem back to the laboratory, and now we intend to take this back to the bedside.

The scientists will start collecting tissue samples from patients within the next six months. If we find the same results in patient samples, we would expect that a simple test for docetaxel resistance could be developed and in clinical use within the next five years, said Dr. Brown. Such a test would mean that those who would not benefit from docetaxel chemotherapy could be spared its side effects, and also reduce costs for healthcare providers.

We think that the changes we have found may represent common drug resistance mechanisms in breast cancer cells, said Dr Brown. We are currently looking at these findings in other cancer types, especially those which are also treated with docetaxel, to see if the results may have a potential in other areas. This is the first time that the genetic pathways involved in the evolution of acquired resistance to docetaxel have been identified in a docetaxel resistant cell line model.


'/>"/>

Contact: Mary Rice
mary@mrcommunication.org
Federation of European Cancer Societies
Source:Eurekalert

Related medicine news :

1. Molecular markers for early diagnosis of breast and ovarian cancer
2. Scientists Developed Map For Brain Molecular Communities
3. Molecular Mechanism Of HIV Infecting The Healthy Cells Discovered.
4. Molecular Flaw Detected in Aggressive Breast Cancers
5. Molecular Computer Developed To perform Calculations From Within Human Body
6. Lung cancer molecular profile discovered by researchers.
7. Molecular Imaging Of Cancer Now Possible, New Hybrid Virus Produced
8. Molecular Basis Of ALS Found
9. New Molecular Treatment Identified To Treat Blood Cell Cancers
10. Researchers Find Molecular "Brake" to Cell Death
11. Solitons Could Power Molecular Electronics, Artificial Muscles
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... Square, PA (PRWEB) , ... March 23, 2017 , ... ... days. That means many students are thinking about summer internships , which can ... lack thereof). , The pros at Garden Media Group, a boutique public relations firm ...
(Date:3/23/2017)... Jersey (PRWEB) , ... March 23, 2017 , ... ... of herbal-based and non-steroidal skincare products, was awarded as winners of American Dreams ... products. This competition was hosted jointly by HSN and Good Housekeeping. , ...
(Date:3/23/2017)... ... March 23, 2017 , ... News Advisory/Interview Opportunity , After six years of ... victory in Europe for public health and the environment and is calling on the ... research and the overwhelming support of European citizens, the European Union (EU) will, beginning ...
(Date:3/23/2017)... ... March 23, 2017 , ... “A Respectful Response To ... Response To Atheist Manifesto” is the creation of published author Richard Hostetter, a ... sixty years. He holds graduate degrees from Kent State University and the University ...
(Date:3/22/2017)... ... 22, 2017 , ... Cosmetic Town, an online plastic surgery ... companion print magazine. The new magazine, scheduled for release in mid-April, includes articles ... board-certified doctors from across the country. , According to the senior editor of ...
Breaking Medicine News(10 mins):
(Date:3/22/2017)... March 22, 2017  Applied BioMath ( www.appliedbiomath.com ... drug research and development, today announced the latest ... Day 2017 is a day full of presentations, ... pharmacology (QSP) community. The focus is to learn ... and accelerating drug research and development. ...
(Date:3/22/2017)... EarlySense , the market leader ... a nationally recognized medical center and a member of Partners ... continued implementation of its Early Detection of Deterioration Project. The ... nurse response time to alarms. ... According to the peer-reviewed paper ...
(Date:3/22/2017)... MARLBOROUGH, Mass. , March 22, 2017 ... that it has completed the acquisition of Cynosure, Inc., ... $66 per share in cash. "We are ... forward to working with Michael Davin and ... in the large, rapidly growing medical aesthetics market," said ...
Breaking Medicine Technology: